Market closedADR
Mereo BioPharma Group/$MREO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Mereo BioPharma Group
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Ticker
$MREO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
33
Website
MREO Metrics
BasicAdvanced
$596M
Market cap
-
P/E ratio
-$0.31
EPS
0.91
Beta
-
Dividend rate
Price and volume
Market cap
$596M
Beta
0.91
52-week high
$5.02
52-week low
$1.95
Average daily volume
772K
Financial strength
Current ratio
6.104
Quick ratio
5.834
Long term debt to equity
0.543
Total debt to equity
9.211
Interest coverage (TTM)
-28.24%
Management effectiveness
Return on equity (TTM)
-62.11%
Valuation
Price to revenue (TTM)
555.075
Price to book
8.2
Price to tangible book (TTM)
8.29
Price to free cash flow (TTM)
-17.961
Growth
Revenue change (TTM)
-88.89%
Earnings per share change (TTM)
26.92%
3-year revenue growth (CAGR)
-72.65%
3-year earnings per share growth (CAGR)
-9.64%
What the Analysts think about MREO
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Mereo BioPharma Group stock.
MREO Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
MREO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
MREO News
AllArticlesVideos
Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points
Seeking Alpha·2 weeks ago
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
GlobeNewsWire·4 weeks ago
Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Mereo BioPharma Group stock?
Mereo BioPharma Group (MREO) has a market cap of $596M as of December 13, 2024.
What is the P/E ratio for Mereo BioPharma Group stock?
The price to earnings (P/E) ratio for Mereo BioPharma Group (MREO) stock is 0 as of December 13, 2024.
Does Mereo BioPharma Group stock pay dividends?
No, Mereo BioPharma Group (MREO) stock does not pay dividends to its shareholders as of December 13, 2024.
When is the next Mereo BioPharma Group dividend payment date?
Mereo BioPharma Group (MREO) stock does not pay dividends to its shareholders.
What is the beta indicator for Mereo BioPharma Group?
Mereo BioPharma Group (MREO) has a beta rating of 0.91. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.